Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

OBJECTIVE: To determine reversion rates from chronic migraine to episodic migraine during long-term erenumab treatment. METHODS: A daily headache diary was completed during the 12-week, double-blind treatment phase of a placebo-controlled trial comparing erenumab 70 mg, 140 mg, and placebo, and week...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B, Tepper, Stewart J, Silberstein, Stephen D, Kudrow, David, Ashina, Messoud, Reuter, Uwe, Dodick, David W, Zhang, Feng, Rippon, Gregory A, Cheng, Sunfa, Mikol, Daniel D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786390/
https://www.ncbi.nlm.nih.gov/pubmed/33269951
http://dx.doi.org/10.1177/0333102420973994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786390/
https://www.ncbi.nlm.nih.gov/pubmed/33269951
http://dx.doi.org/10.1177/0333102420973994

Ejemplares similares